Surface Logix, Inc.

Activbiotics, Inc.

Activbiotics Pharma, LLC

Yingfei Yang

John Henry Van Duzer

Xiang Y Yu

William Bert Geiss

Douglas Gregory Stafford

Arthur F Michaelis

James Michael Siedlecki

Enoch Kim

Alessandra Bartolozzi

Paul Sweetnam

Stewart Campbell

Joseph Raker

Hope Foudoulakis

A Campbell

The present invention relates to compounds which are inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion. These compounds can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its clinical sequelae, for lowering serum lipids, and related ailments. The invention further relates to pharmaceutical compositions comprising the compounds and to methods of treating diseases, such as hypertriglyceridemia, hyperchylomicronemia, atherosclerosis, obesity, and related conditions using the compounds. A method for decreasing apolipoprotein B (apo B) secretion is also provided.

Inhibitors of microsomal triglyceride transfer protein and apo-B secretion

The present invention features rifamycin analogs and methods of using these compounds to treat a variety of microbial infections.

Rifamycin analogs and uses thereof

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3'-hydroxy analogs, and/or various fused ring systems with the benzene ring at the 4&#x2032;,5&#x2032; or 5&#x2032;,6&#x2032; positions.

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3'-hydroxy analogs, 4&#x2032;- and/or 6&#x2032; halo and/or alkoxy analogs, and various 5&#x2032; substituents that incorporate a cyclic amine moiety.

Growing community of inventors

Belmont, MA, United States of America

Yingfei Yang